EmphyCorp, Inc.

Treatment

Idiopathic Pulmonary Fibrosis

(ILD Orphan Drug Designation)

No Adverse Effects

Pulmonary Fibrosis & IPF

(ILD Orphan Drug Designation)

No Adverse Effects

Cystic Fibrosis

(ILD Orphan Drug Designation)

Long COVID Treatment

(No Adverse Effects)

Influenza Treatment & Preventative

(No Adverse Effects)

Unmet Needs - Congestion, Allergic

Rhinitis, COPD, Asthma for Diabetic,

Hypertensive, Pregnant - No Steroids

COPD and Asthma - All Ages

No Adverse Effects

Severe COPD Treatment

(Also Lowered High Blood Pressure)

High Blood Pressure and Pulmonary

Hypertension Treatment

COVID-19 Treatment

(No Adverse Effects)

Racehorses - Increase SaO2

Alzheimer's

Concussions

Cancer Pre-Treatment

OTC Nasal Spray sold US & China

To Date:: (24) Sets of Human Clinical

Trials completed. (6) Peer Reviews.

Drug

N115 Non-Steroidal

Nasal Spray

N115 Non-Steroidal

Nasal Spray

N115 Non-Steroidal

Nasal Spray

N115 Non-Steroidal

Nasal Spray

N115 Non-Steroidal

Nasal Spray

N115 Non-Steroidal

Nasal Spray w/ no

adverse effects

N115 Non-Steroidal

Nasal & Oral Spray

N115 Non-Steroidal

Nasal & Oral Spray

N115 Non-Steroidal

Nasal & Oral Spray

N115 Non-Steroidal

Nasal Spray

N115 Nasal Spray

N115 Nasal Spray and

Oral Spray

EmphyCorp N115 Rx Nasal and Oral Spray Drug Pipeline w/ No Side Effects 9/12/2024 8 Drug Patents (3 New: Hypoxemia & Dyspnea & Coughing, Apoptosis of Myofibroblasts, Coronavirus/Flu) (x = completed)

Phase 2

Χ

Χ

Orphan Drug

NDA

Χ

Χ

Χ

Χ

Χ

Χ

Χ

Pilot Study

Pilot Study

Pilot Study

(1) US and (3) Chinese Approved Nasal Sprays

(3) New Drug Patents for the treatment of all sinus and

lung diseases and slowing/stopping Lung Fibrosis.

Phase 1

Χ

Χ

Χ

Χ

Χ

Χ

Χ

Χ

Pilot Study

Plan

Χ

Pilot Study

Χ

Χ

Χ

NDA

Χ

Note Coughing (Sleep Better)

Improved Lung Function:

Hypoxemia, Dyspnea

Met (8) Medical

Endpoints. Clinically &

Statistically Significant

FEV-1, Hypoxemia,

Dyspnea, Coughing

Phase III - Met (8)

Medical Endpoints

Increases Nasal NO to

kill Viruses/Shut IL-6 Safe Non-Steroidal

for 30 to 60 Million

People in US Alone

FEV-1, Hypoxemia,

Dyspnea, Coughing

.Also reduced High Blood

Pressure to Normal

Discovered in Severe

COPD Patient Clinicals

Increases Nasal NO to

kill Viruses/Shut IL-6

Stop Nasal Bleeding

3 Million Patients Treated

(8) Drug Patents

Phase 3

X - Pivotal

Phase III for

NDA

Protocol

Ready

Χ

Protocol

Ready

Protocol

Ready

Protocol

Readv

Protocol

Ready

Χ